PhoreMost

Executive Summary

PhoreMost is a UK-based biotechnology company founded in 2014 that leverages its NEXT platform, combining next-generation phenotypic screening and artificial intelligence, to systematically explore 'undrugged' biology and identify novel, druggable targets. The platform enables the discovery of first-in-class therapeutics, with a current strategic focus on oncology. By using phenotypic assays that capture disease-relevant biology and AI-driven analysis, PhoreMost aims to unlock targets that have been historically difficult to drug, potentially addressing significant unmet medical needs. The company operates as a private, platform-driven drug discovery entity, primarily targeting cancer therapies.\nIn the competitive landscape of AI-driven drug discovery, PhoreMost differentiates itself through its unique ability to probe the entire proteome for druggable sites, not just known targets. The company has established collaborations and a robust pipeline of early-stage programs. While still private, PhoreMost's approach has attracted attention in the biotech community, and its platform has potential for broad application beyond oncology. Key near-term milestones include advancing lead programs toward preclinical development and securing additional partnerships or financing. The company's ability to demonstrate target validation and therapeutic efficacy in vivo will be critical for its progression. Overall, PhoreMost represents a promising player in the AI-enabled target discovery space.

Upcoming Catalysts (preview)

• Q3 2026Announcement of new partnership/collaboration with a major pharma60% success
• Q4 2026Lead program nomination/IND-enabling studies initiation50% success
• Q2 2026Series B/C financing round70% success